
|Videos|March 31, 2022
AMCP 2022: Katie Lockhart of Magellan Health Talks the Financial Impact of Specialty Drugs & Cost-Impact Models
Author(s)MHE Staff
Katie Lockhart, MA, manager of Magellan Health, addresses her AMCP 2022 conference session on the financial impact of specialty drugs and cost-impact models.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FDA approves first treatment for chronic hepatitis D virus
2
Langlara, third interchangeable biosimilar to Lantus, approved by FDA
3
Cancer patients taking GLP-1s less likely to develop advanced disease | ASCO 2026
4
Family healthcare costs reach $37,824, analysis finds
5






















